Katholieke Universiteit TE Leuven

Katholieke Universiteit TE Leuven, a Belgian non-profit research university operating through its KU Leuven Research & Development division, participates in federal research funding as a prime grant recipient and subcontractor — performing neuroscience, biomedical imaging, medicinal chemistry, and materials science research for U.S. federal agencies, predominantly the National Institutes of Health.

KU Leuven is structured as a non-profit educational institution headquartered in Leuven, Belgium, and holds no federal contracting vehicle seats. The vendor operates across both prime and subcontract roles: 44% of its 54 recent federal awards are prime grants; 56% are sub-awards under prime recipients at U.S. universities. This is exclusively grant and cooperative-agreement work, not federal contracts. KU Leuven has received one small federal contract prime award — a $46,116 definitive contract amendment from the Smithsonian Institution in May 2026 for photometric stereo imaging and data processing, with ultimate completion in September 2026. That contract is an outlier; the institutional footprint is research-grant based.

Customer concentration is heavily skewed toward the National Institutes of Health and its constituent institutes. The National Institute of Dental and Craniofacial Research leads by award count (10 awards), followed by the Department of the Air Force (8 awards), and three NIH institutes with three to five awards each: the National Institute of Allergy and Infectious Diseases, the National Heart Lung and Blood Institute, and the National Institute of Biomedical Imaging and Bioengineering. Together, these five customer entities account for 56% of recent awards. By potential value, the National Human Genome Research Institute anchors the portfolio with $144 thousand in a single award. This measurement discrepancy — NIH-NIDCR dominating by count but NIH-NHGRI leading by dollar magnitude — reflects the nature of KU Leuven's role: the vendor typically receives smaller sub-awards under prime recipients at research universities (University of Pittsburgh, Stanford, Yale, UCLA, Cornell, University of Washington, and others) rather than holding large prime grants directly.

Representative prime grants include an Air Force project grant awarded July 2023 for electric thrusters combining particle-in-cell plasma simulations and machine learning (ultimate completion April 2025); a Research Development and Engineering Command project grant from March 2023 studying the effects of gut bacterial metabolites on stress-induced cognitive impairment (ultimate completion February 2026); and an Office of Naval Research project grant from July 2022 providing support for an international workshop on dynamics of electrons in atomic and molecular nanoclusters (completed February 2023). In its sub-award capacity, KU Leuven delivers medicinal chemistry optimization for antiviral compounds (dengue, SARS-CoV-2, encephalitic alphaviruses) under a Stanford prime award from November 2024; performs MR/PET image reconstruction algorithm development under Stanford sub-awards from June 2024 and May 2024; contributes to the development of an oral pan-coronavirus drug cocktail under University of Washington primes from March and November 2024; and provides neuroimaging and functional ultrasound imaging expertise under awards from Yale, Cornell, and Icahn School of Medicine at Mount Sinai spanning 2023–2024. Combined dollars obligated across all awards total $10.6 million against combined potential value of $206 thousand, a ratio indicating that many awards are multi-year commitments with obligated funding substantially exceeding the current-period potential ceiling.

Activity has grown from four awards in 2022 to eleven in 2024, with one award each in 2025 and 2026 in the current source snapshot. KU Leuven serves 22 distinct federal customer agencies. The vendor's federal footprint is concentrated in biomedical and materials science research, with particular depth in neuroscience, cardiovascular biology, infectious disease, and imaging reconstruction — performed almost entirely through collaborative sub-awards under U.S. university prime recipients rather than through independent federal contracts or large prime grants.